The Immune Checkpoint Inhibitors meeting will enable you to enhance the clinical performance of your immuno-oncology pipeline.Designed with Merck, BMS, Genentech, Novartis, EMD Serono, and Amgen, this industry forum will crack the roadblocks limiting further progress in the field.  Building on the foundations of pioneering academic research this conference will focus uniquely on the challenges for drug developers.